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Abstract 
Factor H (FH) autoantibodies are present in 6-10% of atypical hemolytic uremic syndrome 
(aHUS) patients, most of whom have homozygous deficiency of the FH-related protein FHR-1. 
Although the pathogenic role of the autoantibodies is established, little is known about their 
molecular characteristics and changes over time. Here, we describe the specificity and other 
immunological features of anti-FH autoantibodies in the Spanish and Hungarian aHUS cohorts. 
A total of 19 patients were included and serial samples of 14 of them were available. FH 
autoantibodies from FHR-1 deficient patients (n=13) mainly recognized FH, its SCR19-20 
fragment and FHR-1, but autoantibody specificity in patients who are homo- or heterozygous for 
the CFHR1 gene (n=6) was heterogeneous. No significant changes apart from total antibody 
titer were observed during follow-up in each patient. Fine epitope mapping with recombinant FH 
SCR19-20 containing single amino acid mutations showed significantly reduced binding in 7 out 
of 14 patients. In most cases, autoantibody binding to residues 1183-1189 and 1210-1215 was 
impaired, revealing a major common autoantibody epitope. Avidities showed variations between 
patients, but in most cases the avidity index did not change upon time. Most autoantibodies 
were IgG3, and all but three presented only with kappa or with lambda light chains. Although the 
pathogenic role of anti-FH autoantibodies in aHUS is well established, this study shows 
autoantibody heterogeneity among patients, but no significant variation in their characteristics 
over time in each patient. The presence of a single light chain in 16 out of 19 patients and the 
limited number of recognized epitopes suggest a restricted autoantibody response in most 
patients. 
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1. Introduction 
Hemolytic Uremic Syndrome (HUS) is a rare disease defined by microangiopathic hemolytic 
anemia, thrombocytopenia and acute renal failure. Most cases result from infections with Shiga-
like toxin-producing bacteria, which mainly affect children and have a good prognosis. The 
atypical form of HUS (aHUS) representing 5-10% of cases affects children and adults and has a 
bad prognosis, with high rate of developing end stage renal disease (ESRD) (Loirat and 
Fremeaux-Bacchi 2011; Nester and Thomas 2012).  
Approximately 50% of aHUS patients have mutations or polymorphisms, usually in 
heterozygous form, in the genes encoding proteins of the complement alternative pathway (AP), 
leading to a defective balance between activation and regulation, and thus amplifying the initial 
endothelial damage necessary for aHUS development (Mele, Remuzzi, Noris 2014; Sanchez-
Corral and Melgosa 2010). The penetrance of these mutations is low, and a trigger is required 
for the development of the disease (Noris et al. 2010). Besides complement proteins, mutations 
in thrombomodulin and in diacylglycerol kinase ε have been described in a small cohort of 
aHUS patients (Delvaeye et al. 2009; Lemaire et al. 2013; Rodriguez de Cordoba et al. 2014; 
Sanchez Chinchilla et al. 2014). Mutations in the factor H gene (CFH) are the most prevalent 
genetic alterations representing ~25% of cases (Rodriguez de Cordoba et al. 2014). In addition, 
autoantibodies directed to factor H (FH) are found in ~10% of aHUS cases, but larger 
proportions were also reported, depending on geographical region and ethnicity (Dragon-Durey 
et al. 2005; Hofer, Giner, Jozsi 2014; Sinha et al. 2014). This autoimmune form affects mainly 
children, and has a highly relapsing course with progression to ESRD (Dragon-Durey et al. 
2010). The therapy of anti-FH associated aHUS is not clear, but the goal is the normalization of 
AP regulation, usually removing antibodies with plasmapheresis and immunosuppression 
(Dragon-Durey et al. 2010; Hofer, Giner, Jozsi 2014; Loirat and Fremeaux-Bacchi 2011). Novel 
therapies targeting complement C5 are emerging also in this particular form of aHUS (Diamante 
Chiodini et al. 2014; Noone et al. 2014). 
FH is a 150 kDa plasma glycoprotein that is composed of 20 structural domains named short 
consensus repeats (SCRs). The N-terminal region contains the complement regulatory domains 
(SCRs 1-4), which are responsible for a) the cofactor activity of FH for the Factor I-mediated 
cleavage and inactivation of C3b, b) competition with factor B for C3b binding and thus 
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prevention of the assembly of the AP C3 convertase C3bBb, and c) acceleration of the decay of 
C3bBb. The C-terminal SCRs 18-20 domains are responsible for target discrimination by FH, 
because they mediate binding to glycosaminoglycans expressed on host cells and thus 
protection from damage caused by autologous complement (Blaum et al. 2015; Ferreira, 
Pangburn, Cortes 2010; Pickering et al. 2007).  
There are also five plasma proteins with high sequence and structural homology to FH, 
termed the FH-related proteins (FHRs). The genes encoding FH and the FHRs are located in 
tandem within the Regulator of Complement Activation gene cluster in chromosome 1q32, and 
they share several duplicated intronic-exonic regions, which explains the homology observed in 
this protein family (Abarrategui-Garrido et al. 2009; Skerka et al. 2013). The gene homology 
makes this genomic region prone to rearrangements that may result in hybrid genes and/or 
deletion of CFHR genes, which are associated with various diseases (reviewed in Jozsi et al. 
2015). In this context, about 90% of aHUS patients with FH autoantibodies are homozygous for 
the CFHR3-CFHR1 deletion (Abarrategui-Garrido et al. 2009; Dragon-Durey et al. 2009; Hofer 
et al. 2013). Although this association is not completely understood, autoantibody 
generation/specificity is most likely related with the absence of FHR-1 in these patients. Thus, 
most aHUS-associated FH autoantibodies have been shown to recognize and functionally block 
SCRs 19-20 of FH (Jozsi et al. 2007), and cross-reactivity with FHR-1 has also been found 
(Moore et al. 2010; Strobel et al. 2011). A recent study shows that the autoantibody epitope is 
located on a loop of FH SCR20 that could take a different conformation upon ligand binding, 
and then adopting a similar structure to the homologous site in FHR-1; this may explain the 
association of FHR-1 deficiency with FH autoantibodies due to loss of tolerance (Bhattacharjee 
et al. 2015).  
Whereas the pathogenic role of FH autoantibodies is widely accepted, little is known about 
autoantibody evolution in single patients, and differences among patients. In this study, we have 
characterized FH autoantibodies in serial samples from patients from the Spanish and 
Hungarian aHUS cohorts. Because of individual differences among patients (genetics, 
autoantibody characteristics, clinical presentation, etc.), autoantibody titers cannot be directly 
compared between patients, but changes in autoantibodies in a single patient during follow-up 
should be informative. The goal of this study was to determine whether the molecular 
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characteristics of FH autoantibodies in single aHUS patients change upon time, and to what 
extent these biological features differ among patients.  
 
 
2. Materials and Methods 
The studies were approved by the ethical committees of University Hospital “La Paz”, and the 
respective Hungarian authorities (permission numbers ETT TUKEB 263/PI/11 and 838/PI/12), 
and were performed in accordance with the Declaration of Helsinki. All the patients or their 
relatives and the healthy blood donors gave written informed consent.  
 
2.1. Patients and Controls 
Fourteen Spanish and 5 Hungarian aHUS patients diagnosed with FH autoantibodies were 
studied. Blood samples were obtained at different time points and serum and/or EDTA-plasma 
were kept frozen until use. Patient 17 was a 2 months old patient, with 378 AU/ml FH 
autoantibodies and positive in a sheep erythrocyte lysis assay (39% lysis). Her mother was 
negative in both tests. 
Serial samples from 15 patients were available for analyzing autoantibody levels. Mean time 
of follow-up was 3.7 years, ranging from 2 months to 8 years. All patients were screened for the 
CFHR3-CFHR1 deletion by MLPA method, as previously described (Abarrategui-Garrido et al. 
2009).  
Blood samples from 54 healthy control individuals were also available. 
 
2.2. Detection of FH autoantibodies 
An ELISA assay for anti-FH quantification was performed as previously described (Abarrategui-
Garrido et al. 2009). Microtiter plates were coated overnight with 200 ng of purified FH or with 
HSA as negative control. After washing and blocking with PBS-Tween-20 0.1% (or with 5% 
BSA-PBS-Tween 20), serial dilutions of serum/plasma samples were added and incubated for 1 
hour at 37oC. HRP-conjugated goat anti-human IgG was used as detecting antibody and the 
enzymatic reaction was developed with ABTS or TMB substrate. A positive sample with an 
arbitrary titer of 2000 AU/ml, kindly provided by Dr. Marie-Agnès Dragon-Durey (Hôpital 
Georges Pompidou, Paris, France), was used as reference, and samples above 150 AU/ml 
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were considered positive (mean + 2 SDs obtained from 54 control samples). The established 
cut-off value in the Hungarian laboratory was 110 AU/ml. 
 
2.3. Characterization of IgG subclass and light chain 
IgG subclasses and light chains were identified by ELISA using monoclonal antibodies specific 
for human IgG1, IgG2, IgG3, IgG4, and lambda and kappa light chains (Sigma-Aldrich, 
Budapest, Hungary, and Southern-Biotech, AL, USA) together with HRP-conjugated goat anti-
mouse immunoglobulins (Dako, Hamburg, Germany). 
 
2.4. Binding of autoantibodies to recombinant FH fragments 
Costar High Binding ELISA plates were coated overnight at 4°C with 50 ng/well of either purified 
FH or recombinant FH fragments (SCRs 1-4, SCRs 6-8, SCRs 19-20) produced in yeast (Blanc 
et al. 2012; Jokiranta et al. 2006). After blocking with PBS-BSA 0.1%, wells were incubated with 
patients’ sera, in PBS-BSA 0.1% for 1 h at 37°C. After washing with PBS-Tween-20 0.1%, IgG 
binding was measured using HRP-conjugated anti-human IgG diluted 1/5000 in PBS-Tween 
(Jackson Immunoresearch, Suffolk, UK). Binding to recombinant FHR-1 was also tested in 
samples from all patients. 
For the five Hungarian patients and nine of the Spanish patients, autoantibody binding to 
recombinant proteins produced in insect cells representing FH SCRs 1-4, SCRs 1-7, SCRs 8-
14, SCRs 15-20, and FHR-1 was also measured (Bhattacharjee et al. 2015). 
 
2.5. Binding of autoantibodies to recombinant FH19-20 mutants 
Autoantibody binding to FH SCRs 19-20 was studied in detail by ELISA using recombinant FH 
SCR19-20 fragments with 13 different single amino acid substitutions (Bhattacharjee et al. 
2015). For that purpose, plates were coated with recombinant wild type or mutant FH SCR19-20 
fragments. The applied dilution of each patient’s sera was chosen according to autoantibody 
titers.  
 
2.6. Inhibition of autoantibody binding with anti-FH monoclonal antibodies 
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To further characterize the epitope(s) recognized in FH, autoantibody binding to full-length FH 
was measured in the presence of domain-mapped anti-FH monoclonal antibodies. FH was 
bound to wells in the ELISA plates and then incubated for 15 min with 20 µg/ml anti-FH 
monoclonal antibodies with different domain specificity (A254 [clone 90X]: SCR1, A255: middle 
region, A229: C-terminal region, IXF9: SCR18 (Prodinger et al., 1998), VIG8: SCR19-20 
(Prodinger et al., 1998), and C18: SCR20 (Oppermann et al., 2006). Patient serum samples 
were added and incubated for 1 h. Autoantibody binding was detected using HRP-conjugated 
anti-human IgG antibody.  
 
2.7. Avidity determination 
Avidity of the anti-FH autoantibodies was determined by ELISA, based on the method described 
by Suwannalai et al. (Suwannalai et al. 2011). An appropriate serum dilution for each sample 
was determined previously to ensure that binding to FH was not in saturation and that the OD 
value fell in the range of the standard curve. After 1h of incubation at 20°C, plates were washed, 
and various concentrations of NaSCN (0, 0.25, 0.5, 1, 2, 5 M) were added and incubated for 15 
min at 20ºC to dissociate the FH:anti-FH immune complexes. After washing, remaining bound 
autoantibodies were detected with HRP-conjugated anti-human IgG antibody. The avidity index 
(AI) was calculated as the ratio of autoantibody bound after elution with 0.5 M NaSCN, and the 
autoantibody bound in the absence of NaSCN. 
 
2.8. Circulating FH:anti-FH immune complexes  
Anti-FH monoclonal antibodies OX24 (binding to SCR5) and A229 (binding to the C-terminus), 
and an in-house rabbit polyclonal anti-FH IgG were coated on ELISA plates. After blocking with 
PBS-BSA 1%, patients’ serum samples were added and incubated for 1h at 37°C. The 
presence of FH:anti-FH complexes was then detected with HRP-conjugated anti-human IgG 
antibody. In some assays, the immune complexes were captured on ELISA plates by the mAb 
A255, which recognizes the middle region of FH, and detected as described above. 
Protein G-agarose beads were used to purify the IgG fraction from serum. The eluted proteins 
were separated by 10% SDS-PAGE, and further analyzed by Western blotting using a goat FH 
antiserum (Merck, Budapest, Hungary) as described previously (Strobel et al. 2011). 
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3. RESULTS 
 
3.1. IgG subclasses of the FH autoantibodies 
Identification of IgG subclass and light chain was carried out in all patients with FH 
autoantibodies. All autoantibodies were of the IgG3 isotype, except in patients P18 (IgG1) and 
P13 (IgG1 and IgG3). Light chains were either kappa or lambda except in 3 patients (P1, P2 
and P13) who had FH autoantibodies with both kappa and lambda chains (Table 1). No change 
in the IgG subclass and light chain was observed in single patients when serial samples with 
detectable autoantibodies were available (n = 14; Table 1, Supplementary Figure 1, and data 
not shown). 
 
3.2. Domain mapping of FH autoantibodies 
Table 2 summarizes the results of autoantibody binding to FH and FH fragments, as well as to 
FHR-1. Autoantibodies from all the patients recognized the C-terminal domains of FH, either 
generated in yeast (SCRs 19-20) or in insect cells (SCRs 15-20), and, as it could be expected, 
all of them cross-reacted with FHR-1. The 5 patients with two copies of the CFHR1 gene also 
recognized the N-terminal domains of FH (SCRs 1-4), but only 7 out of the 13 patients with zero 
copy of CFHR1 recognized this FH region. Of note, out of these 12 autoantibodies that bound to 
the FH SCRs 1-4 fragment produced in yeast 7 could be tested for binding to FH SCRs 1-4 
produced in insect cells, and only two out of these 7 autoantibodies showed weak reactivity to 
the latter recombinant protein. In addition, some normal serum samples also showed reactivity 
with recombinant FH SCRs 1-4 produced in yeast (Supplementary Figure 2). 
As serial samples from some patients were collected for several years, we could study whether 
autoantibody specificity changed upon time. Despite all the variability found in autoantibody 
binding among the patients, when serial samples were studied (n = 14) the specificity remained 
unchanged for each patient along time, except in patient P6 whose autoantibodies from the 
initial samples recognized both SCRs 1-4 and 19-20 fragments, and from the later ones only 
bound to the fragment containing SCRs 19-20 (Table 2, Supplementary Figure 3, and data not 
shown. 
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3.3. Inhibition of autoantibody binding to FH using monoclonal antibodies 
To further analyze the FH binding sites, autoantibody binding to full-length FH was measured in 
the presence of domain-mapped anti-FH monoclonal antibodies as an alternative approach. 
These assays showed that mAb C18, which binds to the previously identified autoantibody loop 
on SCR20 (Bhattacharjee et al. 2015), inhibited the interaction of all tested autoantibodies (n = 
14) with FH, except in the case of P19. This finding, together with the variable inhibitory effect of 
other mAbs recognizing the C-terminal region (mAb A229, IXF9 and VIG8) confirmed the C-
terminal specificity of all autoantibodies, and the microheterogeneity in the exact epitope and/or 
affinity of the individual autoantibodies (Fig. 1, Supplementary Figure 4). The mAb binding to 
SCR1 (A254; clone 90X) did not inhibit binding of the autoantibodies to FH. 
 
3.4. Epitope fine mapping of autoantibodies  
In 14 patients, epitope fine mapping with 13 recombinant FH SCR19-20 mutants containing 
single aminoacid exchanges was performed. Less than 80% binding was observed to some of 
the FH SCR19-20 mutants in 6 out of the 14 patients (P3, P4, P6, P8, P16 and P18). Less than 
60% binding was found in the case of three patients (P4, P6, P8), all of them with FHR-1 and 
FHR-3 deficiency. The two most frequent SCR20 subregions in which autoantibody binding was 
impaired comprise residues 1183 to 1189 and residues 1210 to 1215 (Table 3). These residues 
also accumulate mutations already described in aHUS patients (Rodriguez de Cordoba et al. 
2014; Rodriguez et al. 2014). Interestingly, in patients with homozygous FHR-1 deficiency the 
autoantibodies mainly bound to the FH1183-1189 subregion, whereas in patients without FHR-1 
deficiency the FH1203-1215 subregion was mainly recognized. 
 
3.5. Avidity of FH autoantibodies 
Because no detailed studies on the avidity of aHUS-associated FH autoantibodies have been 
reported to date, we set out to analyze this feature in our patients. First, the avidity profile for 
each autoantibody (i.e., the percentage of autoantibody bound after elution with increasing 
concentrations of NaSCN) was determined based on the method described by Suwannalai et al. 
(Suwannalai et al. 2011); representative examples of the avidity profiles for three patients in 
samples taken at different time points are shown in Fig. 2 A-C. To further analyze whether 
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avidity changed over time in single patients, the avidity indexes (i.e., the ratio between 
autoantibody bound after elution with 0.5 M NaSCN and autoantibody bound in the absence of 
NaSCN) in serial samples of several patients were calculated (Figure 2D). One patient 
presented over 20% enhanced avidity index over time, and two patients showed over 20% 
decreased avidity index, but most patients had below 10% difference in the mean avidity index 
between the initial and last sample drawn, even at the longest follow-up times. In addition, these 
experiments allowed us to determine that there was no correlation between the avidity index 
and the autoantibody titer (Figure 2E, Spearman’s r = 0.338, p = 0.0674). 
 
3.6. FH-autoantibody complexes 
Circulating FH:anti-FH complexes were detected in serum samples from all patients using 
different monoclonal antibodies as capture antibodies (Fig. 3A). In serial samples from 
individual patients, the amount of immune complexes largely followed the changes in 
autoantibody titers (Fig. 3B-C) also supporting that there was no significant change in 
autoantibody avidity upon time. The presence of FH in the IgG fraction containing the 
autoantibodies was also confirmed by Western blot in several samples (not shown). 
 
4. DISCUSSION 
Complement dysregulation is the major pathogenic mechanism in aHUS. Approximately 44% of 
aHUS patients carry single or combined mutations in the complement genes CFH, CFI, MCP, 
CFB, C3 or in thrombomodulin (Bresin et al. 2013), and autoimmune forms with FH 
autoantibodies (Dragon-Durey et al. 2005; Hofer, Giner, Jozsi 2014) or FI autoantibodies (Jozsi 
et al. 2014; Kavanagh et al. 2012) are found in ~10% of patients, although the relevance of the 
FI autoantibodies is unclear. The most frequent alterations observed in aHUS are FH defects 
including mutations, risk variants or autoantibodies, and they all have a bad prognosis.  
FH autoantibodies from aHUS patients cause a functional deficiency of FH, interfering with 
FH binding to the AP convertase and with FH-dependent cell protection (Blanc et al. 2012; 
Dragon-Durey et al. 2010; Jozsi et al. 2007). Deficiency of FHR-1 and FHR-3 is strongly 
associated with the presence of FH autoantibodies in aHUS patients. Despite this being the 
most frequent genetic alteration affecting FHR proteins, other genetic defects involving CFHR1 
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have been described, suggesting that the complete deficiency of FHR-1 is the specific factor 
associated with FH autoantibodies in aHUS (Abarrategui-Garrido et al. 2009; Dragon-Durey et 
al. 2009; Jozsi et al. 2008; Moore et al. 2010). Most of these autoantibodies recognize and 
functionally block the C-terminus of FH, and most of them cross-react with FHR-1, because of 
the high homology between SCRs 4-5 of FHR-1 and SCRs 19-20 of FH (Strobel et al. 2011).  
Because little is known about the molecular heterogeneity and evolution of autoantibodies 
during disease course in individual patients, we have analyzed several characteristics of FH 
autoantibodies, including IgG isotype, recognition domain, epitope and avidity, in serial samples 
from aHUS patients from the Spanish and Hungarian cohorts. 
In the patients analyzed in this study, IgG3 was the most prevalent subclass of the FH 
autoantibodies (17/19 patients). One patient also had IgG1 autoantibodies in addition to IgG3, 
while another patient had only IgG1. These results are in accordance with findings of other 
groups (Blanc et al. 2012; Dragon-Durey et al. 2005; Jozsi et al. 2008; Strobel et al. 2011), and 
have consequences for the pathology of the disease, because the half-life, complement 
activating capacity and binding to Fc receptors differ among IgG subclasses. For example, IgG3 
has the shortest half-life (~7 days) among the human IgG subclasses and the longest hinge 
region, allowing more flexibility of the two arms of the molecule. In addition, IgG1 and 
particularly IgG3 are considered the best activators of the classical complement pathway among 
the IgGs. These features could contribute to individual differences in the patients regarding the 
disease course. The main effect of the autoantibodies is, however, the likely blockage of FH 
binding to the self cell surfaces where C3b has been deposited. Therefore, it is possible that the 
clear dominance of IgG3 in FH autoantibodies could be caused by a common mechanism of 
immunization, for example via the cytokine profile in the germinal centre during infection with 
FH-binding microbes. 
Most FH autoantibodies had either kappa or lambda light chain, with slightly higher 
frequency (9:7) of kappa. The simultaneous presence of both light chains was only found in 3 
patients, suggesting oligoclonality of the autoantibody response. There were no changes in 
isotype or light chain of the FH autoantibodies over time. Blanc et al. described that a restriction 
of light chains in FH autoantibody positive patients was found in C3 glomerulopathy (C3G), in 
association with monoclonal gammopathy, but not in autoimmune aHUS (Blanc et al. 2015). 
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Our ELISA results, however, clearly showed predominantly kappa or lambda light chains in 16 
out of the 19 aHUS patients with FH autoantibody (see Supplementary Figure 1 for examples). 
Similarly, in a previous study (Bhattacharjee et al. 2015) only 2 out of 17 studied patients had 
FH autoantibodies with both kappa and lambda light chains. 
Recently, Blanc et al. studied FH:autoantibody complexes in the presence of various NaCl 
concentrations (Blanc et al. 2015), but a detailed analysis regarding the avidity profiles and 
avidity indexes of the FH autoantibodies in serial samples of aHUS patients is currently lacking. 
We therefore analyzed this feature in single patients, and also whether epitope spreading and 
affinity maturation result in a change of autoantibody avidity (Fig. 2). In contrast to previous data 
using NaCl (Blanc et al. 2015), in our experiments using thyocianate for avidity determination, 
which is the standard reagent used in such assays (Pullen et al. 1986), the avidity profiles 
showed considerable variability among aHUS patients. Complete dissociation of FH:anti-FH 
complexes could be achieved in several cases when using the chaotropic salt NaSCN in 1 M or 
higher concentration (Fig. 2A-C). In most of our patients the FH autoantibody titers and the 
amount of FH:anti-FH immune complexes decreased between the acute phase of the disease 
and remission periods, but no significant changes in autoantibody avidity were observed upon 
time (Fig. 2D). About 20% decrease in the avidity index was observed in two patients and 
increase in one patient, independently of the CFHR1 genotype. The reason for the stability of 
the autoantibody avidity is not known, but it could be related to the short time when microbial 
FH-binding proteins are present. 
When analyzing the recognition domain of FH autoantibodies, we found that most of the 
autoantibodies recognized the most C-terminal domains of FH and FHR-1 (Table2). For several 
autoantibodies binding to both the functionally important C- and N-terminal domains of FH was 
observed; notably, N-terminal binding was mainly detected when using recombinant proteins 
produced in yeast, and FH SCRs 1-4 produced in yeast cells also showed increased reactivity 
with several control samples (Supplementary Figure 2). These data, and the lack of inhibition of 
autoantibody binding by the N-terminally binding mAb A254 (clone 90X), which was previously 
shown to inhibit binding of N-terminally binding C3G-associated FH autoantibodies (Blanc et al. 
2015), suggest caution about the specificity of the observed FH N-terminal binding in our patient 
samples. Despite the heterogeneity of autoantibody binding sites, no significant changes in the 
13 
 
recognition domains were observed in each patient during follow up, indicating no epitope 
spreading during the disease course. 
We also performed epitope mapping with recombinant FH SCRs 19-20 fragments containing 
single amino acid mutations (Table 3). A significant reduction in autoantibody binding to some of 
these mutants was particularly evident in patients with FHR-1 deficiency. Impaired autoantibody 
binding was observed with higher frequency to the FH mutants comprising residues 1183 to 
1189 and residues 1210 to 1215. By binding to this region the autoantibodies are likely to block 
function of FH similar to the aHUS-associated mutations that also cluster in the same region 
(Bhattacharjee et al. 2015). This conserved binding site of FH autoantibodies of the FHR-1 
deficient patients fits to the previously proposed model that in FHR-1 deficient individuals a 
conformational change in the SCR20 domain of FH drives autoimmunization (Bhattacharjee et 
al. 2015). Based on that model it has been proposed that the absence of FHR-1 has an impact 
on self tolerance to FH, thus explaining the frequent association between FH autoantibodies 
and the CFHR3-CFHR1 deletion. An explanation for the generation of FH autoantibodies in 
patients with circulating FHR-1 is, however, still lacking. 
FH autoantibodies have also been identified in patients with C3G, (Blanc et al. 2015; 
Goodship et al. 2012; Jozsi et al. 2014; Nozal et al. 2012). In this disease, autoantibodies show 
a binding preference for the N-terminal complement regulatory domains of FH (SCRs1-4) and 
they do not associate with CFHR1 deletion. These FH autoantibodies in C3G are likely 
pathogenic because they block the regulatory functions of FH SCRs1-4 and thus lead to 
uncontrolled alternative pathway activation in plasma. Therefore, there is a clear difference 
between FHR-1 deficiency-associated autoantibodies against the C terminus of FH in aHUS, 
where cell protection from complement attack by FH is perturbed, and the N-terminally binding 
FH autoantibodies in C3G. N-terminally binding autoantibodies in aHUS could cause a more 
subtle dysfunction of FH; these autoantibodies may limit the correct orientation and activity of 
FH on surface-bound C3b, depending on the exact binding site within FH SCRs1-4 domains. 
In summary, these data confirm recent results (Bhattacharjee et al. 2015) regarding the main 
epitope recognized by autoantibodies from two other aHUS cohorts, and describe molecular 
characteristics of individual antibodies, including the evolution of antibody avidity in single 
patients for the first time. Although the pathogenic role of FH autoantibodies is well established 
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in aHUS, our study reveals heterogeneity among patients, but no epitope spreading or 
significant variation in their biological characteristics over time in each patient. These 
autoantibodies seem to reflect a restricted immune response, as suggested by the presence of 
a single light chain in most patients and the limited number of epitopes they recognize. 
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FIGURE LEGENDS 
 
Figure 1: Inhibition of autoantibody binding to FH with monoclonal antibodies.  
The percentage of autoantibody binding to full-length FH in the presence of domain-mapped 
monoclonal anti-FH antibodies is shown. 100%: autoantibody binding to FH without addition of 
mAb. A254 is directed to FH SCR1, A255 binds the FH middle region, A229 and VIG8 in the C-
terminal region, C18 in SCR20 and IXF9 in SCR18. Data are means + SD from three different 
experiments, except for P7 (one experiment). 
 
Figure 2: Avidity of FH autoantibodies. 
A) to C) show the avidity profile of FH autoantibodies from three patients over time. Avidity is 
represented as the percentage of autoantibody which remained bound after elution with 
increasing concentration of NaSCN. D) Variation of avidity index (AI) between the initial and the 
last sample obtained from patients. E) Lack of correlation between AI and autoantibody titer. 
The AI was calculated as the ratio of autoantibodies bound to immobilized FH after elution with 
0.5 M NaSCN, and autoantibodies bound in the absence of NaSCN.  Spearman’s r = 0.338, 
95% confidence interval = (-0.036,0.630), p = 0.0674. 
 
Figure 3: Presence of circulating FH:anti-FH immune complexes.  
A) Detection of FH:anti-FH immune complexes in patient P4 at disease onset and 7 years later 
by using different monoclonal antibodies (A229, Ox24, A255) or a polyclonal anti-FH antibody 
(rb34) as capture antibodies. B) -F) Evolution of free and FH-bound autoantibodies over time in 
patients P9, P10, P11, P12 and P13. 
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Table 1. Summary of aHUS patients with FH autoantibodies and their characterization 
Patient Age at 
onset 
CFHR1 
genotype 
Follow-up time of 
the included 
samples in months 
(nº analyzed 
samples) 
Autoantibodies 
titer range 
(AU/ml) 
IgG 
subclass 
Light 
chain 
P1 5 y 
-/- 19 (1) 380 
IgG3 κ+λ 
P2 4 y -/- 63 (7) 6840-570 IgG3 κ+λ 
P3 8 y -/- 79 (6) 2625-525 IgG3 κ 
P4 7 y -/- 2 (3) 1000-800 IgG3 λ 
P5 6 y 
-/- 90 (1) 1700 
IgG3 κ 
P6 5 y -/- 37 (12) 1811-252 IgG3 λ 
P7 8 y -/- 24 (5) 8160-175 IgG3 κ 
P8 10 y 
-/- One sample 3250 
IgG3 κ 
P9 11y 
-/- 3 (3) 851-220 
IgG3 λ 
P10 8 y 
-/- 21 (3) 4817-653 
IgG3 λ 
P11 8 y 
-/- 63 (2) 1539-100 
IgG3 λ 
P12 8 y 
-/- 40 (2) 9433-421 
IgG3 λ 
P13 6 y 
-/- 22 (3) 3718-628 
IgG1+IgG3 κ+λ 
P14 6 y 
-/+ 15 (3) 8600-2682 
IgG3 λ 
P15 3 y 
+/+ 75 (4) 3600-Negative 
IgG3 κ 
P16 11 y +/+ 3 (2) Positive 
(weak) 
IgG3 κ 
P17 2 m 
+/+ 27 (1) 378 
IgG3 κ 
P18 9 y +/+ 3 (2) 353-Negative IgG1 κ 
P19 42 y 
+/+ 13 (2) 224-204 
IgG3 κ 
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Patien
t 
CFHR1 
genotyp
e 
Relative Binding to FH Relative Binding to FH 
FHR
-1 
Analyzed samples (time after 
onset) complet
e FH 
SCRs 1-
4a 
SCRs 6-8 
a 
SCRs 19-20 
a 
SCRs 1-4 
b 
SCRs 1-7 
b 
SCRs 8-14 
b 
SCRs 15-20 
b 
P1 -/- + ++ - + n.t.   n.t.  n.t.   n.t.  + 1 (19 m) 
P2 -/- +++ - - ++ 
- 
- 
- + ++ 
10 
(3,relapse,9,16,25,28,43,53,58,
64 m) 
P3 -/- +++ - - ++ - - (+) ++ ++ 8 (0,1,9,31,70,73,78,81 m) 
P4 -/- +++ - - ++ - - (+) + ++ 5 (9,13,16,23,33 d) 
P5 -/- ++ + + +  n.t.  n.t. n.t. n.t. + 1 (90 m) 
P6 -/- ++ + - ++ 
- 
- 
(+) + + 
12 (9,15,22 
d;1,2,2.2,2.4,4,6,19,20,39 m) 
P7 -/- ++ - - +++ - - - ++ ++ 4 (4 d; 7,25,28 m) 
P8 -/- ++ +++ - ++ n.t. n.t. n.t. n.t. ++ 1 
P9 -/- + ++ + + - - - + + 2 (1, 7 d) 
P10 -/- ++ - - + - - - + + 2 (0, 21 m) 
P11 -/- ++ ++ ++ ++ - - - + + 2 (0, 2 m) 
P12 -/- + ++ (+) + - - - ++ + 2 (0, 40 m) 
P13 -/- +++ - - ++ - - - ++ ++ 2 (0, 24 m) 
P14 -/+ +++ - - - - - - + + 5 (8,12,17,23,36 m) 
P15 +/+ ++ ++ ++ ++ + + - - ++ 5 (5,6,64,76,82 m) 
P16 +/+ + + - ++ - - - (+) + 2 (61,64 m) 
P17 +/+ + + + + n.t. n.t. n.t. n.t. + 1 (27 m) 
P18 +/+ + ++ + + n.t. n.t. n.t. n.t. + 2 (15 d; 4 m) 
P19 +/+ + ++ - +++ (+) (+) (+) + ++ 2 (1,13 m) 
Table 2. Binding sites of FH autoantibodies. The table summarizes binding sites of FH autoantibodies to the different FH fragments used. a: recombinant 
FH fragments produced in yeast. b: recombinant FH fragments produced in insect cells. +++ represents strong binding, ++ medium binding, + weak binding, 
(+) uncertain binding; all expressed in relation to the signal obtained for autoantibody binding to full-length FH. n.t.: not tested (due to limited availability of 
some of the samples). d, days; m, months.
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Table 3: Epitope mapping of FH autoantibodies on SCRs 19-20 of FH. 
Autoantibody binding to recombinant FH SCRs 19-20 fragments with single point mutations, expressed as percentage of binding to the WT FH SCRs 19-20 
fragment. Data are mean of at least three different experiments. 
Patient D1119G Q1139A W1157L R1182A W1183L T1184R K1186A K1188A L1189R E1198A R1203A R1210A R1215Q 
P1              
P2              
P3              
P4              
P5              
P6              
P7              
P8              
P15              
P16              
P17              
P18              
P19              
Percentage of binding is indicated in the table as follows: 
>100 80-99 60-79 40-59 <40 
 
12 13 14 15 16 17 18 19 203 4 5 6 9 111 7 82 10
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Supplementary Figure 1. Examples of FH autoantibody isotypes in aHUS patients during follow‐up. 
Serial serum samples of patients were analyzed as described in Methods for IgG isotype (A) and for 
light chains (B). 
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Supplementary  Figure  2.  Reactivity  of  10  normal  serum  samples  with  the  recombinant  FH 
fragments produced in Pichia pastoris. Purified FH and the recombinant proteins were immobilized 
in microplate wells  as  described  in  Methods.  After  blocking  and  incubation with  sera  of  healthy 
donors,  IgG binding was detected using HRP‐conjugated anti‐human  IgG antibody. A representative 
experiment is shown. 
 
 
Supplementary Figure 3. Examples of reactivity of FH autoantibodies with various recombinant FH 
fragments  during  follow‐up.  Serial  serum  samples  of  patients  were  analyzed  as  described  in 
Methods  for  binding  to  purified  FH,  FH  SCRs  1‐4,  SCRs  6‐8  and  SCRs  19‐20  (produced  in  Pichia 
pastoris). 
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Supplementary Figure 4. Effect of anti‐FH mAbs on autoantibody binding to FH from serial samples 
of patients P11 and P12. Binding of the autoantibodies in the presence of mAbs was determined as 
described in Methods. C18: anti‐FH mAb that binds to SCR20 of FH. A254: anti‐FH mAb that binds to 
SCR1 of FH. mIgG: purified mouse IgG, used as non‐specific control antibody. 
